Hydroxyurea Effectively Reduces Extreme Thrombocytosis (Platelets >1000 × 10⁹/L)
Hydroxyurea is the first-line cytoreductive agent for extreme thrombocytosis (platelet count >1000 × 10⁹/L) in myeloproliferative neoplasms, effectively lowering platelet counts to reduce thrombotic and hemorrhagic complications. 1, 2
Mechanism and Efficacy
Hydroxyurea works by suppressing myeloproliferation and can rapidly reduce platelet counts, often achieving a 50% reduction within 24-48 hours when initiated at appropriate doses 3. The drug is particularly critical in extreme thrombocytosis because:
- Platelet counts ≥1000 × 10⁹/L carry paradoxical bleeding risk due to acquired von Willebrand syndrome, where excessive platelets consume von Willebrand factor 3, 4
- Thrombotic risk remains elevated despite the bleeding tendency, requiring urgent platelet reduction 5
Dosing Strategy for Extreme Thrombocytosis
Initial dosing: Start at 15-30 mg/kg/day (typically 1000-3000 mg/day in adults), with higher doses (3000 mg/day) used urgently when bleeding complications are present 6, 3, 7
Target platelet count: The optimal but unvalidated target in essential thrombocythemia is <400 × 10⁹/L 2. For extreme thrombocytosis with bleeding, aim for rapid reduction below 1000 × 10⁹/L within 24-48 hours 3.
Dose adjustments: Base dosing on actual or ideal body weight (whichever is less). For patients >80 kg, doses up to 2.5 g/day may be required 2, 6.
Treatment Response Criteria
Hydroxyurea resistance/inadequate response in essential thrombocythemia is defined as 2:
- Platelet count remaining >600 × 10⁹/L after 3 months of at least 2 g/day (2.5 g/day if >80 kg body weight)
- Platelet count <400 × 10⁹/L but with WBC <2500/μL (indicating excessive myelosuppression)
- Development of unacceptable toxicities (leg ulcers, fever, cytopenias)
Critical Monitoring Requirements
Weekly complete blood counts are mandatory during hydroxyurea therapy 6. Watch for:
- Myelosuppression (most common toxicity): Leukopenia typically appears first, followed by thrombocytopenia and anemia 6
- Hemolytic anemia: If acute jaundice or hematuria develops with worsening anemia, check LDH, haptoglobin, reticulocyte count, and Coombs test. Discontinue hydroxyurea if hemolysis confirmed 6
- Cutaneous vasculitis: Particularly in patients with prior interferon exposure. Requires immediate discontinuation 2, 6
Important Clinical Pitfalls
Acquired von Willebrand syndrome recognition: In patients with platelets >1000 × 10⁹/L presenting for procedures (like bone marrow biopsy), start hydroxyurea before the procedure to prevent catastrophic bleeding 3. If bleeding occurs, use high-dose hydroxyurea (3000 mg/day) urgently alongside supportive measures (desmopressin, FFP, tranexamic acid).
Dose titration failures: Real-world data shows only 6.4% of patients receive the guideline-recommended ≥2 g/day dosing, and 57.1% maintain hematocrit >45% despite treatment 8. Actively titrate doses upward rather than accepting suboptimal control—many patients require 2-2.5 g/day for adequate response.
Renal impairment: Reduce dose by 50% if creatinine clearance <60 mL/min or in ESRD (give post-dialysis on dialysis days) 6.
When Hydroxyurea Fails
If platelet count remains >600 × 10⁹/L after 3 months at maximum tolerated doses (≥2 g/day), consider second-line agents 1, 2:
- Pegylated interferon-alpha (preferred in younger patients needing long-term therapy)
- Anagrelide (selective platelet-lowering agent, though evidence of non-inferiority to hydroxyurea is moderate quality)
- Ruxolitinib (for hydroxyurea-resistant/intolerant patients, though primarily studied in polycythemia vera)
Long-term Considerations
Hydroxyurea carries carcinogenic risk with long-term use, including secondary leukemia and skin cancers 6. This risk must be balanced against the immediate thrombotic/hemorrhagic dangers of extreme thrombocytosis. Monitor for secondary malignancies and advise sun protection.
Prophylactic folic acid is recommended to prevent macrocytosis 6.